Ardelyx to Report Q1 2026 Earnings on April 30

Biopharmaceutical company to host webcast and conference call to discuss financial results and business update.

Apr. 16, 2026 at 12:18pm

Got story updates? Submit your updates here. ›

A minimalist, high-end studio still life photograph featuring a glass beaker, a white medical pill capsule, and a sleek metal syringe arranged elegantly against a clean, monochromatic grey background, conceptually representing the precision and innovation of the pharmaceutical industry.Ardelyx's upcoming earnings report will provide insights into the company's progress in developing and commercializing innovative treatments for unmet medical needs.Waltham Today

Ardelyx, Inc., a commercial-stage biopharmaceutical company, announced that it will host a webcast and conference call on Thursday, April 30, 2026, at 4:30 p.m. Eastern Time to discuss its financial results and provide a business update from the first quarter of 2026.

Why it matters

As a publicly traded biopharmaceutical company, Ardelyx's quarterly earnings reports are closely watched by investors to gauge the performance and progress of its approved products and pipeline. The company's ability to execute on its commercial strategy and advance its drug candidates is crucial for its long-term success.

The details

Ardelyx will provide details on the financial results and business updates from the first quarter of 2026 during the webcast and conference call. The company's two approved products in the U.S. are IBSRELA (tenapanor) and XPHOZAH (tenapanor), and its pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor.

  • Ardelyx will host the webcast and conference call on Thursday, April 30, 2026, at 4:30 p.m. Eastern Time.
  • The company will discuss financial results and provide a business update from the first quarter of 2026.

The players

Ardelyx, Inc.

A commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs.

Got photos? Submit your photos here. ›

The takeaway

Ardelyx's upcoming earnings report will provide insights into the company's commercial execution, pipeline progress, and overall financial health as it continues to develop and commercialize innovative treatments for unmet medical needs.